Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
life sciences
national blog main
national top stories
san francisco blog main
biotech
new york blog main
san diego blog main
san francisco top stories
indiana blog main
indiana top stories
new york top stories
san diego top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
texas blog main
clinical trials
deals
fda
gene therapy
bluebird bio
boston
department of health and human services
drug prices
hemophilia
medicare
regeneron pharmaceuticals
rna interference
scott gottlieb
What
long
8
×
drug
awaited
drugs
house
plan
prices
ago
details
gene
help
lower
medicine
medicines
therapy
trump
unveiled
white
abandoning
adapt
administration
afternoon
anathema
anticipated
aren’t
baggage
bio
biotechs
blueprint
canada
canadian
cells
cellular
changes
cheaper
companies
considering
cost
costly
countries
Language
unset
unknown
Current search:
long
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details